N4 PHARMA PLC

Regulatory Filings • Jun 27, 2023

National Storage Mechanism | Additional information /*<![CDATA[*/ /**/ /**/ /**/ h2{margin-right:0cm;margin-left:0cm;font-size:18.0pt;font-family:"Times New Roman","serif";font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .ai{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ai{}p.i,li.i,div.i{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.bb{font-size:10.0pt}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt; text-align:center}span.ba{font-size:10.0pt;line-height: 107%}span.ay{font-size:10.0pt;line-height:107%}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify}span.ax{font-size:10.0pt;line-height:107%; font-family:"Trebuchet MS","sans-serif"}p.bf{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal} span.av{font-size:10.0pt; background:white}p.bg{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.bh{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:-21.3pt;text-indent:21.3pt;background: white}span.as{font-size:10.0pt;line-height:107%;color:black}table.bi{width:15.0cm;margin-left:15.9pt;border-collapse:collapse}td.ap{width:265.6pt;padding:0cm 5.4pt 0cm 5.4pt}span.aq{font-size:10.0pt;line-height:107%;font-family:"Calibri Light","sans-serif"}td.ao{width:138.05pt;padding:0cm 5.4pt 0cm 5.4pt}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.am{font-size:10.0pt;line-height:107%; color:black} p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: 12.0pt;background:white}p.bk{margin-right:0cm;margin-left:0cm;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;background:white}span.ak{font-size:10.0pt;font-family:"Calibri","sans-serif";color:black} .fr-view-element{font-family: sans-serif;font-size: 12pt;line-height: 140%;padding: 20px;box-sizing: border-box;overflow-x: auto;min-height: 60px;text-align: left;margin-bottom: 10px;width: 837px;} .fr-view-element img{padding: 0 1px;} .fr-view-element .ai{margin: 63.8pt 1.6cm 62.35pt 1.6cm;} .fr-view-element p{font-size: 10pt;} /**/ /**/ /**/ /*]]>*/

RNS Number : 9375D

N4 Pharma PLC

27 June 2023

Reach - Non-Regulatory

27 June 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

Grant Award for Professor Chengzhong Yu

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce it will be supporting the University of Queensland as part of a recent grant award by the Australian Research Council.

The University of Queensland has announced that Professor Chengzhong Yu, Senior Group Leader, Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded a $402,115 grant to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid (mRNA) therapies. The new nanoparticle will be based on the Company's patented nuvec® nanoparticle that it has licensed exclusively from the University of Queensland.

N4 Pharma will work with Professor Yu to tackle the current challenges in manufacturing mRNA therapeutics, by building new knowledge in custom-design of functional nanomaterials for mRNA delivery. mRNA is a highly lucrative field of therapeutic science and is emerging as a major drug platform.

A copy of the full announcement can be found here: https://aibn.uq.edu.au/article/2023/06/linkage-grants-catapult-lab-ideas-production-line

Nigel Theobald, Chief Executive Officer of the Company, commented:

"We are pleased to continue our close collaboration with Professor Yu and work on new ways to build on the performance of our Nuvec® nanoparticle together."

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director	Via IFC Advisory
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking)	Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker IFC Advisory Limited Financial PR Graham Herring Zach Cohen	Tel: +44 (0)20 3657 0050 Tel: +44 (0)20 3934 6630

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRANKABPNBKDBAB